PTYLTD
    • Insights
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Insights

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic

By Topic

Compound Interest Calculator

Compound Interest Calculator: Shows How Patient Savers Let Time Do the Heavy Lifting

Oct 9, 2026
Proactive Equities Team

Moneysmart’s compound interest calculator shows how earning interest on interest lifts savings, super and investments, and why starting early, even with modest deposits, can make a big difference to a balance over the long run.

Amaero (ASX: 3DA)

Amaero (ASX: 3DA): US IPO Moves Closer after Loan Deal Frees Up Cash

Oct 9, 2026
Proactive Equities Team

Amaero (ASX: 3DA) has filed a third amendment to its US IPO registration and renegotiated its EXIM loan, releasing restricted cash and delaying a key liquidity test, while preliminary quarterly figures show revenue alongside heavy cash burn.

Electro Optic Systems (ASX: EOS)

Electro Optic Systems (ASX: EOS): Secures A$700m Counter-Drone Contract, Accelerating Its Defence Ambitions

Oct 9, 2026
Proactive Equities Team

Electro Optic Systems (ASX: EOS) has signed its largest-ever contract, a nation-wide counter-drone system for a Gulf state. The deal is conditional on guarantees and export licences, making delivery and funding the key tests still ahead.

Cettire (ASX: CTT)

Cettire (ASX: CTT): Growth Potential Meets Valuation Risk

Oct 9, 2026
Proactive Equities Team

Cettire expands globally via its asset-light luxury marketplace, leveraging European price arbitrage and Asian market entries. While operating cash flow improved and debt remains zero, statutory net losses, thin margins, and working capital deficits create material going-concern risks.

MAAS Group (ASX: MGH)

MAAS Group (ASX: MGH): Share Price Plummets Amid Reports of Firmus IPO Repricing, Rattling Investors

Oct 8, 2026
Proactive Equities Team

MAAS Group (ASX: MGH) shares fell sharply on reports that Firmus may lower its IPO price, putting its stake and its JLE electrical contracts in focus days after completing its $1.61 billion construction materials sale.

AFT Pharmaceuticals (ASX: AFP)

AFT Pharmaceuticals (ASX: AFP): Double-Digit Growth, Cuban Partnership, and Fridge-Free Strategy Strengthen Long-Term Outlook

Oct 8, 2026
Proactive Equities Team

AFT Pharmaceuticals (ASX: AFP) reports double-digit growth across all divisions, a US launch with Mark Cuban’s Cost Plus Drugs, and fridge-free vaccine validation, while holding its $300 million revenue and $28–32 million profit guidance for FY27.

...

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics
Videos

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...121314...82
Page 13 of 82